<head><meta charset="UTF-8"></head><link href="../../style.css" rel="stylesheet"><head>
		<script src="../../jquery-3.6.0.min.js"></script>
		</head>
	 <button onclick="ShowLag01()">EN_CN</button>
	 <button onclick="ShowLag0()">EN</button>
	 <button onclick="ShowLag1()">CNS</button>
	 <button onclick="ShowLag2()">CNT</button>
	<script>
	function ShowLag0(){
		$('.laguage0').show();
		$('.laguage1').hide();
		$('.laguage2').hide();
	}
		function ShowLag1(){
		$('.laguage1').show();
		$('.laguage0').hide();
		$('.laguage2').hide();
	}
		function ShowLag2(){
		$('.laguage2').show();
		$('.laguage1').hide();
		$('.laguage0').hide();
	}
	function ShowLag01(){
		$('.laguage2').hide();
		$('.laguage1').show();
		$('.laguage0').show();
	}
	</script><p class="pubdate" >2021-08-16T15:55:27+00:00</p><p class="fly_title laguage0"  >Combating future viruses</p><p class="fly_title laguage1"  >抗击未来病毒</p><p class="fly_title laguage2"  >抗擊未來病毒</p><p class="title laguage0" >Predicting viral evolution may let vaccines be prepared in advance</p><p class="title laguage1" >预测病毒进化或许可以提前备好疫苗</p><p class="title laguage2" >預測病毒進化或許可以提前備好疫苗</p><p class="rubric laguage0"  >New techniques could programme people’s immune systems against future pathogens</p><p class="rubric laguage1"  >新技术也许能诱导人体免疫系统准备好对付尚未出现的病原体</p><p class="rubric laguage2"  >新技術也許能誘導人體免疫系統準備好對付尚未出現的病原體</p><img class="laguage0" src="images/_en_GB_0_quipimage.jpeg" ></img><img class="laguage1"  src="images/_zh_CN_0_quipimage.jpeg" ></img><img class="laguage2"  src="images/_zh_CN_0_quipimage.jpeg" ></img><p class="mainpage laguage0">GENERALLY, IMMUNE systems mount responses only against pathogens that have already infected the bodies they are protecting. Science, though, can shorten the path to immunity by vaccination. This involves presenting the immune system with harmless or lookalike versions of dangerous pathogens so that it may create antibodies and killer cells hostile to the real thing in advance of any actual infection, thereby reducing its danger.
        </p><p class="mainpage laguage1">一般来说，免疫系统只会攻击已感染人体的病原体，发挥保护作用。不过，科学让人们找到了获得免疫力的捷径——接种疫苗。其原理是让免疫系统接触经过无害处理的危险病原体或与之相似的病原体，让人体有可能在实际感染前产生能对抗真正病原体的抗体和杀伤细胞，从而降低危险。
        </p><p class="mainpage laguage2">一般來說，免疫系統只會攻擊已感染人體的病原體，發揮保護作用。不過，科學讓人們找到了獲得免疫力的捷徑——接種疫苗。其原理是讓免疫系統接觸經過無害處理的危險病原體或與之相似的病原體，讓人體有可能在實際感染前產生能對抗真正病原體的抗體和殺傷細胞，從而降低危險。
      </p><p class="mainpage laguage0">Like immune responses themselves, however, vaccination generally has to wait for the appearance of the pathogen in question before it can do its stuff. There is therefore a delay between a pathogen’s arrival on the scene and the deployment of a vaccine against it. That delay costs lives. Even in the case of covid-19, which has prompted the fastest vaccine-development programme the world has ever witnessed, millions are reckoned to have died by the time vaccinations began to be given in the rich world at the end of 2020.
        </p><p class="mainpage laguage1">但是，与自然免疫反应一样，疫苗接种通常要等需要对付的病原体出现后才能实施。所以在病原体来袭时，疫苗的接种总是会慢一步。这种延误要付出生命的代价。虽说新冠疫情催生了全球史上进展最迅速的疫苗研发，但到去年底富裕世界开始接种疫苗时，估计已有数百万人死于新冠肺炎。
        </p><p class="mainpage laguage2">但是，與自然免疫反應一樣，疫苗接種通常要等需要對付的病原體出現後才能實施。所以在病原體來襲時，疫苗的接種總是會慢一步。這種延誤要付出生命的代價。雖說新冠疫情催生了全球史上進展最迅速的疫苗研發，但到去年底富裕世界開始接種疫苗時，估計已有數百萬人死於新冠肺炎。
      </p><p class="mainpage laguage0">But, just as vaccination introduces immune systems to pathogens that are remote from them in space, new techniques which have come to the fore during the current pandemic offer the possibility of introducing them to pathogens that are remote from them in time—pathogens, indeed, that have not yet evolved, but which are likely to do so in the future. Thanks to a combination of high-throughput DNA-sequencing technologies and modern machine-learning it is now possible not merely to observe which variants of a virus are circulating, but also to suggest how they are likely to change. Understanding in this way what a virus might look like in the months and years to come gives those designing vaccines and therapies a leg up, enabling them to prime more immune systems sooner, so that fewer people die.
        </p><p class="mainpage laguage1">但是，正如疫苗接种让免疫系统可以接触到在空间上与之距离甚远的病原体，在这场全球疫情中暂露头角的新技术也让免疫系统有可能接触到在时间上与之距离甚远的病原体，也就是目前尚未出现但很可能在未来演变出来的病原体。在高通量DNA测序和现代机器学习技术的辅助下，现在我们不仅可以检测到某个病毒的哪些变种正在传播，还可以预测病毒可能发生的变异。通过这种方式了解病毒在未来数月和数年内可能出现的变异，疫苗和疗法的研发人员可以赢得先机，帮助更多人更早建立免疫，从而减少死亡人数。
        </p><p class="mainpage laguage2">但是，正如疫苗接種讓免疫系統可以接觸到在空間上與之距離甚遠的病原體，在這場全球疫情中暫露頭角的新技術也讓免疫系統有可能接觸到在時間上與之距離甚遠的病原體，也就是目前尚未出現但很可能在未來演變出來的病原體。在高通量DNA測序和現代機器學習技術的輔助下，現在我們不僅可以檢測到某個病毒的哪些變種正在傳播，還可以預測病毒可能發生的變異。通過這種方式了解病毒在未來數月和數年內可能出現的變異，疫苗和療法的研發人員可以贏得先機，幫助更多人更早建立免疫，從而減少死亡人數。
      </p><p class="mainpage laguage0">The starting point for these predictions is the sort of work going on in the laboratory of Jesse Bloom, a virologist at the Fred Hutchinson Cancer Research Centre, in Seattle. Dr Bloom and his colleagues grow variants of coronavirus spike protein (the molecule which such viruses use to attach themselves to cells they are about to infect) in Petri dishes. They then scan through these to discern which mutations have what effects.
        </p><p class="mainpage laguage1">这类预测的起点是病毒学家杰西·布卢姆（Jesse Bloom）的实验室正在推进的那类研究。在位于西雅图的弗雷德-哈钦森癌症研究中心（Fred Hutchinson Cancer Research Centre），布卢姆与同事们在培养皿中培养冠状病毒刺突蛋白（这种病毒用以附着于受体细胞的蛋白分子）的变体，然后逐个扫描它们，分辨什么突变会产生什么影响。
        </p><p class="mainpage laguage2">這類預測的起點是病毒學家傑西·布盧姆（Jesse Bloom）的實驗室正在推進的那類研究。在位於西雅圖的弗雷德-哈欽森癌症研究中心（Fred Hutchinson Cancer Research Centre），布盧姆與同事們在培養皿中培養冠狀病毒刺突蛋白（這種病毒用以附着於受體細胞的蛋白分子）的變體，然後逐個掃描它們，分辨什麼突變會產生什麼影響。
      </p><p class="mainpage laguage0">They have named this technique deep mutational scanning. It uses an array of yeast cells that have been genetically modified to express a part of the spike protein called the receptor-binding domain (RBD). As the yeast cells churn out their RBDs, many emerge, thanks to errors inherent in their production, with slight deviations in their structures from that of the original wild-type virus. Dr Bloom’s team then test the RBDs from each yeast cell to see how tightly they bind to ACE2, a receptor protein found on the surfaces of some human cells, to which the coronavirus attaches itself before entering those cells. RBDs that bind tightly have their underlying genomes sequenced, to determine which mutations are present.
        </p><p class="mainpage laguage1">他们把这种技术命名为深度突变扫描。它利用了一大批酵母细胞，这些细胞经过基因改造而能表达刺突蛋白中名为受体结合域（receptor-binding domain，以下简称RBD）的部分。当酵母细胞产生自己的RBD时，由于复制过程中不可避免会出现错误，许多新出现的RBD在结构上与原始野生病毒略有不同。布卢姆的团队测试每个酵母细胞的RBD，看它们与ACE2（人体某些细胞表面的受体蛋白，新冠病毒会附着其上，继而入侵细胞）结合的紧密度，再对那些能紧密结合的RBD做基因测序，以确定存在哪些突变。
        </p><p class="mainpage laguage2">他們把這種技術命名為深度突變掃描。它利用了一大批酵母細胞，這些細胞經過基因改造而能表達刺突蛋白中名為受體結合域（receptor-binding domain，以下簡稱RBD）的部分。當酵母細胞產生自己的RBD時，由於複製過程中不可避免會出現錯誤，許多新出現的RBD在結構上與原始野生病毒略有不同。布盧姆的團隊測試每個酵母細胞的RBD，看它們與ACE2（人體某些細胞表面的受體蛋白，新冠病毒會附着其上，繼而入侵細胞）結合的緊密度，再對那些能緊密結合的RBD做基因測序，以確定存在哪些突變。
      </p><p class="mainpage laguage0">When Dr Bloom’s team ran this scan in the summer of 2020, on spike from a version of the virus then circulating, they spotted a mutation called N501Y which appeared to confer a binding advantage. A few months later, that mutation appeared in the Alpha variant, which for several months was dominant across much of the world. Dr Bloom says it would be “charitable” to say that he and his colleagues had predicted the emergence of N501Y. It was by no means the only mutation of interest to turn up. But even so, having a limited set of such mutations to focus on is useful for narrowing the field of research.
        </p><p class="mainpage laguage1">去年夏天，布卢姆的团队对当时流行的一种新冠病毒毒株的刺突蛋白进行深度突变扫描，发现了一个名为N501Y的突变，似乎能提高病毒与受体结合的亲和力。几个月后，该突变出现在阿尔法毒株中，该毒株在世界大部分地区广泛流行了几个月。布卢姆表示，他和同事们“算是”预测到了N501Y的出现，但实际上这绝非唯一值得关注的可能突变。即便如此，可以聚焦一组数量有限的突变的确有助缩小研究范围。
        </p><p class="mainpage laguage2">去年夏天，布盧姆的團隊對當時流行的一種新冠病毒毒株的刺突蛋白進行深度突變掃描，發現了一個名為N501Y的突變，似乎能提高病毒與受體結合的親和力。幾個月後，該突變出現在阿爾法毒株中，該毒株在世界大部分地區廣泛流行了幾個月。布盧姆表示，他和同事們“算是”預測到了N501Y的出現，但實際上這絕非唯一值得關注的可能突變。即便如此，可以聚焦一組數量有限的突變的確有助縮小研究範圍。
      </p><p class="mainpage laguage0">Getting the message across
        </p><p class="mainpage laguage1">信息传达
        </p><p class="mainpage laguage2">信息傳達
      </p><p class="mainpage laguage0">One firm taking advantage of that narrowing is Flagship Labs 77, a company based in Boston that has until recently been working in secret. FL77, as it is known for short, is a spin out from Flagship Pioneering, a biotechnology incubator run by Noubar Afeyan, a venture capitalist. Moderna, a trailblazer of the messenger- RNA-based technology that helped speed up the production of coronavirus vaccines, was also a Flagship Pioneering company, and Mr Afeyan is its chairman.
        </p><p class="mainpage laguage1">位于波士顿的“旗舰实验室77”（Flagship Labs 77，以下简称FL77）便受惠于此。这家之前一直行事低调的公司出自风险资本家努巴·阿费扬（Noubar Afeyan）经营的生物技术孵化器“旗舰先锋”（Flagship Pioneering）。旗舰先锋培育的另一家公司莫德纳（Moderna）开创了mRNA技术，加速了新冠病毒疫苗开发。阿费扬是莫德纳的董事长。
        </p><p class="mainpage laguage2">位於波士頓的“旗艦實驗室77”（Flagship Labs 77，以下簡稱FL77）便受惠於此。這家之前一直行事低調的公司出自風險資本家努巴·阿費揚（Noubar Afeyan）經營的生物技術孵化器“旗艦先鋒”（Flagship Pioneering）。旗艦先鋒培育的另一家公司莫德納（Moderna）開創了mRNA技術，加速了新冠病毒疫苗開發。阿費揚是莫德納的董事長。
      </p><p class="mainpage laguage0">FL77’s researchers are trying to combine experimental data of the sort Dr Bloom is collecting with computation, in order to predict how viruses may evolve. That information could be used to develop vaccines and therapeutic antibodies pre-emptively. Whereas Dr Bloom’s laboratory predicts only single mutational hops, FL77 can currently manage five or six. The firm calls its system “Global Pathogen Shield”. The details remain confidential, but in June it published a paper outlining the project’s goals. This described the scale of the challenge involved in keeping pace with viral evolution—namely that biology is so diverse that even looking at a small slice of possible mutations leads to a problem which rapidly grows beyond the plausible limits of observation, to one on the scale of counting and categorising all of the atoms of which Earth is composed.
        </p><p class="mainpage laguage1">FL77的研究人员正尝试把布卢姆正在收集的那类实验数据结合以运算，以预测病毒可能如何演变。这些信息可用于提前研发疫苗和治疗性抗体。布卢姆的实验室只能预测单个突变，而FL77目前可预测五六个。FL77把该预测系统称为“全球病原体盾牌”（Global Pathogen Shield）。研究细节仍然保密，但FL77在6月发表的一篇文章概述了该项目的目标。文章指出，研发要赶上病毒变异的速度挑战极大，因为生物变化异常多样，即使只研究一小部分可能出现的突变也会导致研究范围越来越大，最终无法观察，就像要统计和分类地球上所有原子那么难。
        </p><p class="mainpage laguage2">FL77的研究人員正嘗試把布盧姆正在收集的那類實驗數據結合以運算，以預測病毒可能如何演變。這些信息可用於提前研發疫苗和治療性抗體。布盧姆的實驗室只能預測單個突變，而FL77目前可預測五六個。FL77把該預測系統稱為“全球病原體盾牌”（Global Pathogen Shield）。研究細節仍然保密，但FL77在6月發表的一篇文章概述了該項目的目標。文章指出，研發要趕上病毒變異的速度挑戰極大，因為生物變化異常多樣，即使只研究一小部分可能出現的突變也會導致研究範圍越來越大，最終無法觀察，就像要統計和分類地球上所有原子那麼難。
      </p><p class="mainpage laguage0">The conventional response to such overwhelming odds has been observation rather than experimentation. The World Health Organisation’s Global Influenza Surveillance and Response System does this for flu. It monitors which viruses are circulating in the southern hemisphere when it is winter there, in order to focus attention on which strains will be relevant during the next northern-hemisphere winter, and vice versa. During the coronavirus pandemic, organisations such as Nextstrain and GISAID have kept track of variants of SARS-CoV-2 in a similar way.
        </p><p class="mainpage laguage1">面对这不可胜数的变异可能，一般的方法是观察而非做实验。世卫组织的全球流感监测与应对系统就用这种方法追踪流感。当南半球进入冬季，该系统就会监测哪些病毒在南半球流行，以集中分析哪些毒株将在之后的北半球冬季流行，如此循环往复。在新冠疫情期间，Nextstrain和全球共享流感数据倡议组织（GISAID）等组织以类似的方式追踪新冠病毒变异。
        </p><p class="mainpage laguage2">面對這不可勝數的變異可能，一般的方法是觀察而非做實驗。世衛組織的全球流感監測與應對系統就用這種方法追蹤流感。當南半球進入冬季，該系統就會監測哪些病毒在南半球流行，以集中分析哪些毒株將在之後的北半球冬季流行，如此循環往複。在新冠疫情期間，Nextstrain和全球共享流感數據倡議組織（GISAID）等組織以類似的方式追蹤新冠病毒變異。
      </p><p class="mainpage laguage0">FL77 aims to take this much further—not only tracking which variants of a virus are where, but also predicting how they will evolve. It does this by feeding into a piece of software called Octavia data from a scaled-up version of Dr Bloom’s deep mutational scanning that runs assays on between 1m and 10m variants.
        </p><p class="mainpage laguage1">FL77的目标远不止于此，它不仅要追踪病毒变体的传播情况，还要预测它们将如何演变。它的做法是运用布卢姆的深度突变扫描技术的加强版，对一百万到一千万个变体做检测分析，把所得数据输入名为Octavia的软件中。
        </p><p class="mainpage laguage2">FL77的目標遠不止於此，它不僅要追蹤病毒變體的傳播情況，還要預測它們將如何演變。它的做法是運用布盧姆的深度突變掃描技術的加強版，對一百萬到一千萬個變體做檢測分析，把所得數據輸入名為Octavia的軟件中。
      </p><p class="mainpage laguage0">Octavia’s job is to recognise patterns in the Petri-dish data—for example, which of the millions of mutations tend to lead to tighter binding, and also which lead to poorer neutralisation by antibodies—and then to extrapolate those across all possible variants of spike. This leads to predictions about which mutations will defeat antibodies, and which will spread more easily. That, says the paper, “makes it possible to define a protective antibody repertoire”, whether through vaccination or manufacturing of antibody proteins themselves. FL77 calls this an “antibody net”.
        </p><p class="mainpage laguage1">Octavia的任务是识别培养皿数据中的模式（例如，在数以百万计的突变中，哪些会导致病毒与受体更紧密结合，哪些会导致抗体中和作用减弱），然后在所有可能的刺突变体中推导这些模式，从而预测哪些突变将打败抗体，哪些突变会更易传播。文章写道，这“使我们有可能列出一份保护性抗体清单”，通过疫苗接种或制造抗体蛋白本身来建立保护。FL77称之为“抗体安全网”。
        </p><p class="mainpage laguage2">Octavia的任務是識別培養皿數據中的模式（例如，在數以百萬計的突變中，哪些會導致病毒與受體更緊密結合，哪些會導致抗體中和作用減弱），然後在所有可能的刺突變體中推導這些模式，從而預測哪些突變將打敗抗體，哪些突變會更易傳播。文章寫道，這“使我們有可能列出一份保護性抗體清單”，通過疫苗接種或製造抗體蛋白本身來建立保護。FL77稱之為“抗體安全網”。
      </p><p class="mainpage laguage0">Dr Bloom, who is advising FL77, and who holds patents on deep mutational scanning, says the value of these kinds of predictions has become clear with the development of messenger-RNA vaccines. These are not just quick to make, but quick to update. Their manufacturing process starts with the gene for the viral protein that the immune system is desired to attack, and ends with a strand of RNA which encodes that specific protein.
        </p><p class="mainpage laguage1">拥有深度突变扫描技术专利的布卢姆是FL77的顾问，他表示，随着mRNA疫苗的发展，这类预测的价值已经明确。mRNA疫苗不仅可以快速制造出来，也可以快速更新。其制造流程从获取想让免疫系统攻击的病毒蛋白的基因入手，最终生产出能编码这种蛋白的一段RNA。
        </p><p class="mainpage laguage2">擁有深度突變掃描技術專利的布盧姆是FL77的顧問，他表示，隨着mRNA疫苗的發展，這類預測的價值已經明確。mRNA疫苗不僅可以快速製造出來，也可以快速更新。其製造流程從獲取想讓免疫系統攻擊的病毒蛋白的基因入手，最終生產出能編碼這種蛋白的一段RNA。
      </p><p class="mainpage laguage0">In covid-19 vaccines, the protein in question is spike. Updating vaccines to take account of predicted variants of spike is merely a matter of inserting the relevant genetic code at the start of the manufacturing process. At the least, such predictions would permit a library of candidate vaccines to be held ready, in anticipation of rapid manufacturing. At its most ambitious, FL77 imagines vaccinating people against variants of a pathogen that are not yet circulating, but are likely to.
        </p><p class="mainpage laguage1">新冠疫苗要对付的病毒蛋白就是刺突蛋白。要根据刺突蛋白变异的预测来升级疫苗，只需在生产的开始阶段加入相应的遗传密码。这些预测至少可以让人们建好一个候选疫苗库，以备快速投产。而FL77最大胆的设想是根据预测提前接种，对抗尚未流行但很可能传播开来的病原体变体。
        </p><p class="mainpage laguage2">新冠疫苗要對付的病毒蛋白就是刺突蛋白。要根據刺突蛋白變異的預測來升級疫苗，只需在生產的開始階段加入相應的遺傳密碼。這些預測至少可以讓人們建好一個候選疫苗庫，以備快速投產。而FL77最大膽的設想是根據預測提前接種，對抗尚未流行但很可能傳播開來的病原體變體。
      </p><p class="mainpage laguage0">Deep mutational scanning may have other uses, too. Gabriel Victora, an immunologist at Rockefeller University in New York, thinks predicting the evolution of a pathogen in this way will be useful not just for designing antibodies and vaccines, but also for detecting parts of the virus which change only rarely, and aiming antibodies at what would thus be reliable targets.
        </p><p class="mainpage laguage1">深度突变扫描或许还有其他用途。纽约洛克菲勒大学的免疫学家加布雷尔·维克托劳（Gabriel Victora）认为，以这种方式预测病原体的演变不仅可以用于设计抗体和疫苗，也可以用于检测病毒中极少发生变异的部分，让抗体瞄准这些可靠的攻击目标。
        </p><p class="mainpage laguage2">深度突變掃描或許還有其他用途。紐約洛克菲勒大學的免疫學家加布雷爾·維克托勞（Gabriel Victora）認為，以這種方式預測病原體的演變不僅可以用於設計抗體和疫苗，也可以用於檢測病毒中極少發生變異的部分，讓抗體瞄準這些可靠的攻擊目標。
      </p><img class="laguage0" src="images/_en_GB_16_quipimage.jpeg" ></img><img class="laguage1"  src="images/_zh_CN_16_quipimage.jpeg" ></img><img class="laguage2"  src="images/_zh_CN_16_quipimage.jpeg" ></img><p class="mainpage laguage0">This, though, is difficult. The shape of any given segment of a protein depends on the rest of the molecule of which it is a part. Yet, for the immune system, the shape of its target is a crucial feature that it needs to learn in order to recognise its foe. So, though predictive approaches like FL77’s might spot segments of viral proteins which are unlikely to change, getting the immune system to look at them specifically is difficult, because expressing an isolated protein segment in a way that makes it the same shape as it is when it is part of a bigger structure is tricky.
        </p><p class="mainpage laguage1">但这并不容易。蛋白分子任一片段的形状都取决于该分子的其他构成部分。而对免疫系统来说，要识别出攻击目标，一个必须掌握的关键特征就是目标的形状。因此，尽管FL77的这类预测方法可能会发现病毒蛋白中不太会变异的片段，但要让免疫系统学会专门分辨出它们是件难事，因为很难找到方法来孤立表达蛋白分子的某个片段而使其形状与它作为整体的一部分时的形状一致。
        </p><p class="mainpage laguage2">但這並不容易。蛋白分子任一片段的形狀都取決於該分子的其他構成部分。而對免疫系統來說，要識別出攻擊目標，一個必須掌握的關鍵特徵就是目標的形狀。因此，儘管FL77的這類預測方法可能會發現病毒蛋白中不太會變異的片段，但要讓免疫系統學會專門分辨出它們是件難事，因為很難找到方法來孤立表達蛋白分子的某個片段而使其形狀與它作為整體的一部分時的形狀一致。
      </p><p class="mainpage laguage0">A more brute-force approach is simply to show the immune system all of the protein structures that are likely to emerge in future, so that it makes antibodies against the lot. Dr Victora says that immune systems have no known limit to their capacity to absorb information about pathogens. Instead, the problem with this approach may come if the system preferentially makes antibodies to some of the predicted variant proteins, but not others.
        </p><p class="mainpage laguage1">一种更“蛮力”的方法是干脆让免疫系统认识所有未来可能出现的蛋白质结构，这样系统就会针对这些蛋白分子制造不同的抗体。维克托劳表示，据目前所知，免疫系统吸收病原体信息的能力并无上限。但如果免疫系统选择性地只对某些被预测出的变异蛋白产生抗体，对其他蛋白没反应，那这种方法可能就有问题了。
        </p><p class="mainpage laguage2">一種更“蠻力”的方法是乾脆讓免疫系統認識所有未來可能出現的蛋白質結構，這樣系統就會針對這些蛋白分子製造不同的抗體。維克托勞表示，據目前所知，免疫系統吸收病原體信息的能力並無上限。但如果免疫系統選擇性地只對某些被預測出的變異蛋白產生抗體，對其他蛋白沒反應，那這種方法可能就有問題了。
      </p><p class="mainpage laguage0">Strain gauge
        </p><p class="mainpage laguage1">毒株应变仪
        </p><p class="mainpage laguage2">毒株應變儀
      </p><p class="mainpage laguage0">Seasonal flu vaccines already grapple with this problem when updating immune systems with information about the strain predicted to be circulating in the coming winter. Even after vaccination, immune systems may tend to make antibodies against the old virus instead. It is not clear whether the same thing will happen with updated messenger-RNA vaccines.
        </p><p class="mainpage laguage1">季节性流感疫苗就已经遭遇这个问题。基于会在即将到来的冬季流行的新毒株的预测，这些疫苗向人体免疫系统更新有关这些新毒株的信息。但即使在接种完成后，免疫系统可能仍倾向于制造针对旧毒株的抗体。目前还不清楚更新mRNA疫苗时是否也会如此。
        </p><p class="mainpage laguage2">季節性流感疫苗就已經遭遇這個問題。基於會在即將到來的冬季流行的新毒株的預測，這些疫苗向人體免疫系統更新有關這些新毒株的信息。但即使在接種完成後，免疫系統可能仍傾向於製造針對舊毒株的抗體。目前還不清楚更新mRNA疫苗時是否也會如此。
      </p><p class="mainpage laguage0">No programme will ever be able to predict the evolution of the entire array of pathogens which can plausibly infect human beings. But for those already known to pose a threat, systems like Octavia may be able to see far enough into the future to offer benefits. “We don’t have to be able to predict arbitrarily,” says Dr Bloom. “We don’t need to predict mutation in a decade. Just a radius of five to six mutations from where we are now. That’s good enough.”
        </p><p class="mainpage laguage1">没有任何程序能预测所有可能感染人类的病原体的演变。但是对于那些已知会构成威胁的病原体，Octavia这类系统力所能及的预测结果也许仍足以造福人类。“我们没必要做出任意的预测，”布卢姆说，“我们不需要预测十年内出现的突变，在目前的基础上预测大概五到六个突变就够了。”
        </p><p class="mainpage laguage2">沒有任何程序能預測所有可能感染人類的病原體的演變。但是對於那些已知會構成威脅的病原體，Octavia這類系統力所能及的預測結果也許仍足以造福人類。“我們沒必要做出任意的預測，”布盧姆說，“我們不需要預測十年內出現的突變，在目前的基礎上預測大概五到六個突變就夠了。”
      </p><p class="mainpage laguage0">FL77 is already doing this. The most radical version of the firm’s vision—vaccinating against variants and strains of pathogens that are yet to emerge—is some way off, if it ever happens. Protecting people by programming their immune systems against future pathogens, not just those already circulating, would be a fundamental shift in the meaning, purpose and ethics of vaccination. But even in the absence of that, pathogen prediction should soon serve to speed existing sorts of vaccination programmes. And every increase in the speed of vaccine development means thousands of saved lives. ■
        </p><p class="mainpage laguage1">FL77已经在这样做了。该公司最具革新性的愿景是针对尚未出现的病原体变体和毒株接种疫苗，但即使最终能实现，也有待时日。针对未来可能出现而非已在传播的病原体诱导免疫系统来保护人们免受侵害，这将从根本上改变疫苗接种的意义、目的和伦理。就算做不到这一点，病原体预测应该很快将能帮助加速现有的疫苗接种计划。而疫苗研发的每次提速都意味着成千上万生命获救。
        </p><p class="mainpage laguage2">FL77已經在這樣做了。該公司最具革新性的願景是針對尚未出現的病原體變體和毒株接種疫苗，但即使最終能實現，也有待時日。針對未來可能出現而非已在傳播的病原體誘導免疫系統來保護人們免受侵害，這將從根本上改變疫苗接種的意義、目的和倫理。就算做不到這一點，病原體預測應該很快將能幫助加速現有的疫苗接種計劃。而疫苗研發的每次提速都意味着成千上萬生命獲救。
      </p><p class="line"  ></p>